Additionally, tivozanib, a selective TKI targeting VEGFR1, VEGFR2, and VEGFR3, has demonstrated significant improvements in median PFS compared to sorafenib in two pivotal phase III clinical trials, underscoring its potential as a promising therapeutic option for advanced RCC (178, 179). This evidence concerns the gene KDR and renal cell carcinoma.